Pfizer Covid 19 Vaccine, recent ga ee vaccine gurinchi manam chala vintunnam. Just 10 months lo anni ways lo testing chesi vaccine ni develop chesaru, and trails lo kuda 95% effective results tho success ayindi. So now Pfizer and its partner BioNTech confirmed that they will apply for emergency use authorization for their coronavirus vaccine..
Pfizer CEO Albert Bourla said that..
Critical milestone in our journey to deliver a COVID-19 vaccine to the world and we now have a more complete picture of both the efficacy and safety profile of our vaccine, giving us confidence in its potential, The companies will be ready to distribute the vaccine candidate within hours after authorization..
Timeline of Pfizer`s run up to this historic moment:
March 17: Pfizer and BioNTech announce plans to develop a Covid-19 vaccine using BioNTech`s technology platform.
April 29: Testing of four vaccine candidates begins with volunteers in Germany. Five other countries are part of the testing pool.
May 5: Testing expands to include the US.
July 1: One of four vaccine candidates appears to rev up the immune system, is well tolerated.
July 22: Trump administration agrees to buy 100 million vaccine doses, with an option for 500 million more.
July 27: Late-stage testing begins for 30,000 volunteers.
September 8: CEOs of 9 pharma giants, including Pfizer and BioNTech, pledge they will not be rushed by politics or extraneous factors.
November 8: Pfizer receives data from independent trial monitors who analysis test results.
November 9: Pfizer announces the vaccine appears to be about 90 per cent effective, based on 94 infections in a pool of more than 43,000 volunteers.
November 18: Pfizer and BioNTech release a second batch of interim results saying their two-dose coronavirus vaccine candidate is 95 per cent effective and also protects the most vulnerable people in older age groups from the risk of dying from the virus.
November 20: Pfizer announces intent to submit application to US regulators for emergency use authorization.
India in talks with Pfizer, says AIIMS director..
Dr Randeep Guleria, director of All India Institute of Medical Sciences (AIIMS) Delh, today said that India is in talks with Pfizer-BioNTech Covid-19 vaccine.
He said, "We have two challenges in front of us now. One to break the transmission chain, two to make the vaccine available to all."
For India, RNA vaccines are going to be very expensive...
The coronavirus vaccine by Pfizer, which is based on a novel technology that uses synthetic mRNA to activate the immune system against the virus, needs to be kept at minus 70 degrees Celsius (-94 F) or below...
It would be a challenge to distribute Pfizer's coronavirus vaccine in rural areas of India or poor countries where resources are tight.
A logistical obstacle..
This will be a challenge in all settings because hospitals even in big cities do not have storage facilities for a vaccine at that ultra-low temperature. In fact, one of the most prestigious US hospitals, the Mayo Clinic in Rochester said it does not currently have that capability.
Dr. Gregory Poland from Mayo Clinic said that..
We're a major medical center and we don't have storage capacity like this. That will be true for everybody. This is a logistical obstacle.
